EcoDrugPlus

Glutamate Receptor, Ionotropic, Ampa 3b

Ensembl ID : ENSDARG00000037498
Gene Symbol: GRIA3B
11 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 4b

Ensembl ID : ENSDARG00000059368
Gene Symbol: GRIA4B
5 Cross references
252 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSDARG00000027828
Gene Symbol: GRIN1A
5 Cross references
205 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1b

Ensembl ID : ENSDARG00000025728
Gene Symbol: GRIN1B
19 Enzyme and pathways 5 Cross references
152 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a, A

Ensembl ID : ENSDARG00000034493
Gene Symbol: GRIN2AA
8 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a, B

Ensembl ID : ENSDARG00000070543
Gene Symbol: GRIN2AB
5 Cross references
225 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSDARG00000030376
Gene Symbol: GRIN2BB
19 Enzyme and pathways 5 Cross references
256 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2ca

Ensembl ID : ENSDARG00000078149
Gene Symbol: GRIN2CA
5 Cross references
249 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2cb

Ensembl ID : ENSDARG00000077560
Gene Symbol: GRIN2CB
8 Enzyme and pathways 5 Cross references
247 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2d, A

Ensembl ID : ENSDARG00000086207
Gene Symbol: GRIN2DA
5 Cross references
215 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 3ba

Ensembl ID : ENSDARG00000005364
Gene Symbol: GRIN3BA
4 Cross references
226 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 3bb

Ensembl ID : ENSDARG00000098667
Gene Symbol: GRIN3BB
5 Cross references
223 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).